Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Summary as of Jun 27, 2018

June 27, 2018 - By Susanne Funderburg

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 3 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:COLL) has 100% bullish analysts. 4 are the (NASDAQ:COLL)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. In Tuesday, January 23 report Piper Jaffray maintained it with “Buy” rating and $33.0 target. In Monday, February 12 report Piper Jaffray maintained the stock with “Buy” rating. On Monday, June 11 Cantor Fitzgerald initiated Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. In Sunday, February 11 report Jefferies maintained the stock with “Buy” rating. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

11/06/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $40.0000 Initiate
12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain

COLL is hitting $25.65 during the last trading session, after decreased 0.58%.Currently Collegium Pharmaceutical, Inc. is uptrending after 169.07% change in last June 27, 2017. COLL has also 11,110 shares volume. The stock outperformed the S&P 500 by 156.50%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is valued at $847.58 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news released recently go to: Seekingalpha.com, Schaeffersresearch.com, Benzinga.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Premarket analyst action – healthcare” released on June 12, 2018, “2 Healthcare Stocks Expected to Skyrocket” on June 12, 2018, “Cantor Fitzgerald Out Bullish On Collegium As ‘Leading Company’ In Pain Management” with a publish date: June 12, 2018, “Collegium Announces CEO Succession” and the last “Piper Jaffray Remains Bullish on Collegium Pharma (COLL) Ahead of FDA Committee Meeting” with publication date: June 26, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: